SHIN NIPPON BIOMEDICAL LABORATORIES, LTD.

2395.TJapan

15 filed reports · 304 financial concepts

Latest figures

Group totals as stated in the company’s own filed reports, each with a link to its report. The change is against the same period a year earlier.

Latest fiscal year

Revenue

¥32.5B

FY2026 · to Mar 31, 2026

up +0.3% vs ¥32.4B

Half-year report

Net income

¥4.53B

FY2026 · to Mar 31, 2026

down −6.8% vs ¥4.86B

Annual report

Operating income

¥2.65B

FY2026 · to Mar 31, 2026

down −11.1% vs ¥2.99B

Annual report

Latest half year

Revenue

¥17.6B

H1 FY2027 · to Sep 30, 2026

up +19.0% vs ¥14.8B

Half-year report

Net income

¥2.17B

H1 FY2027 · to Sep 30, 2026

up +109% vs ¥1.04B

Half-year report

Operating income

¥1.56B

H1 FY2027 · to Sep 30, 2026

up +3,054% vs ¥49.3M

Half-year report

Filed reports

15 reports · Dec 2021 to Sep 2026

Each report counts once it has at least one extracted financial fact.

Report typeReportsFactsPeriods
Annual · annual securities reportEDINET52,526Mar 2022 to Mar 2026
Half Year · half-year securities reportEDINET3790Sep 2024 to Sep 2026
Q3 · quarterly securities reportEDINET3574Dec 2021 to Dec 2023
Half Year · quarterly securities reportEDINET2459Sep 2022 to Sep 2023
Q1 · quarterly securities reportEDINET2395Jun 2022 to Jun 2023

Documents

PeriodTypePeriod endPublishedFactsSource
FY2027 H1half-year securities report2026-09-302026-11-10342Open
FY2026annual securities report2026-03-312026-06-25858Open
FY2026 H1half-year securities report2025-09-302025-11-07221Open
FY2025annual securities report2025-03-312025-06-27429Open
FY2025 H1half-year securities report2024-09-302024-11-06227Open
FY2024annual securities report2024-03-312024-06-25423Open
FY2024 Q3quarterly securities report2023-12-312024-02-02244Open
FY2024 H1quarterly securities report2023-09-302023-11-07234Open
FY2024 Q1quarterly securities report2023-06-302023-08-02237Open
FY2023annual securities report2023-03-312023-06-28419Open
FY2023 Q3quarterly securities report2022-12-312023-01-31169Open
FY2023 H1quarterly securities report2022-09-302022-10-31225Open

Financial data

304 concepts · 4,744 facts

Each concept is one reported line item or metric. The count is how many values of it are held, across the periods shown.

GAAP289 concepts · 3,885 facts · Mar 2020 to Sep 2026

  • EPS (Basic)44 · Mar 2020 to Sep 2026
  • Equity-to-asset ratio, Key financial data37 · Mar 2020 to Sep 2026
  • Net Assets37 · Mar 2020 to Sep 2026
  • Ordinary profit (loss), Key financial data37 · Mar 2020 to Sep 2026
  • Revenue37 · Mar 2020 to Sep 2026
  • Total Assets37 · Mar 2020 to Sep 2026
  • Net assets, Key financial data34 · Mar 2020 to Sep 2026
  • Advances received32 · Mar 2021 to Sep 2026
  • Allowance for doubtful accounts-CA-by group32 · Mar 2021 to Sep 2026
  • Capital surplus32 · Mar 2021 to Sep 2026
  • Cash and deposits32 · Mar 2021 to Sep 2026
  • Income taxes payable32 · Mar 2021 to Sep 2026
  • Intangible assets32 · Mar 2021 to Sep 2026
  • Inventory32 · Mar 2021 to Sep 2026
  • Investments and other assets32 · Mar 2021 to Sep 2026
  • Investment securities32 · Mar 2021 to Sep 2026
  • Land32 · Mar 2021 to Sep 2026
  • Lease liabilities - NCL32 · Mar 2021 to Sep 2026
  • Long-term borrowings32 · Mar 2021 to Sep 2026
  • Notes and accounts receivable - trade, and contract assets32 · Mar 2021 to Sep 2026
  • Other-CA32 · Mar 2021 to Sep 2026
  • Other-CL32 · Mar 2021 to Sep 2026
  • Other-IOA32 · Mar 2021 to Sep 2026
  • Property, plant and equipment32 · Mar 2021 to Sep 2026

Segment15 concepts · 859 facts · Dec 2020 to Sep 2026

  • Operating Income139 · Dec 2020 to Sep 2026
  • Revenue135 · Dec 2020 to Sep 2026
  • Transactions with other segments120 · Dec 2020 to Sep 2026
  • Revenues from external customers116 · Dec 2020 to Sep 2026
  • Average number of temporary employees64 · Mar 2022 to Mar 2026
  • Number of employees64 · Mar 2022 to Mar 2026
  • Total Assets45 · Mar 2021 to Mar 2026
  • Increase in property, plant and equipment and intangible assets42 · Mar 2021 to Mar 2026
  • Depreciation, Segment Information39 · Mar 2021 to Mar 2026
  • Equity in earnings (losses) of affiliates25 · Mar 2021 to Mar 2026
  • Impairment losses - EL22 · Mar 2021 to Mar 2026
  • Capital expenditures, Overview of capital expenditures, etc.16 · Mar 2022 to Mar 2026
  • Amortization of goodwill-SGA11 · Mar 2023 to Mar 2026
  • Goodwill11 · Mar 2023 to Mar 2026
  • Research and development expenses, Research and development activities10 · Mar 2022 to Mar 2026

Segments

859 facts

Figures broken down by business line, region, product or another axis the company reports on.

Operating segments14 members · 859 facts

  • ReportableSegmentsMember134 · Dec 2020 to Sep 2026
  • OperatingSegmentsNotIncludedInReportableSegmentsAndOtherRevenueGeneratingBusinessActivitiesMember124 · Dec 2020 to Sep 2026
  • CROMember104 · Dec 2020 to Sep 2026
  • TotalOfReportableSegmentsAndOthersMember100 · Dec 2020 to Sep 2026
  • TranslationalResearchMember82 · Mar 2021 to Mar 2026
  • MedipolisMember70 · Mar 2021 to Mar 2026
  • ReconcilingItemsMember68 · Dec 2020 to Sep 2026
  • MedipolisReportableSegmentsMember52 · Dec 2020 to Sep 2026
  • TranslationalResearchReportableSegmentsMember38 · Dec 2020 to Sep 2026
  • USAssetManagementReportableSegmentMember30 · Mar 2024 to Sep 2026
  • CROServicesMember22 · Mar 2022 to Mar 2026
  • CorporateSharedMember20 · Mar 2022 to Mar 2026
  • CROServicesReportableSegmentsMember12 · Jun 2021 to Jun 2023
  • UnallocatedAmountsAndEliminationMember3 · Mar 2021 to Mar 2023

Text from filings

Management commentary and risk factors, extracted from SEC filings only.

No commentary or risk-factor text for this company.

Earnings calls

Transcripts with management claims and analyst questions, one per fiscal period.

No earnings-call transcripts for this company.

Executive media

Podcasts, interviews and conference appearances by the company's executives, with their claims.

No media appearances for this company.

Ask about this company in your AI model

Connect FactIQ to Claude, ChatGPT or another AI model (how to install), then paste this prompt.

Use FactIQ to get the revenue, net income and operating income of SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395.T) from its filed reports, for the last five fiscal years and the latest quarter or half year. Link each figure to its filing, and chart the trend.

Works once FactIQ is connected

Reports are counted as filed reports with at least one served fact. Counts are read from the database (last read Nov 19, 2026) and refreshed every few hours.

SHIN NIPPON BIOMEDICAL LABORATORIES, LTD. (2395.T): FY2026 revenue ¥32.5B · FactIQ